Bishoy Faltas, MD, Weill Cornell Medicine, New York, NY, provides an overview of treatment options for patients with upper tract urothelial cancer. Combination therapies, which take into account the unique disease biology of this tumor, incorporating FGFR3 inhibitors with CDK4/6 inhibitors or immune checkpoint inhibitors are currently under investigation. This interview took place at the ASCO GU Cancers Symposium 2024 in San Francisco, CA.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
